Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > January 5, 2026
Daily News
January 5, 2026
- Cabinet OKs FY2026 Tax Reform Package, Creates Strategic Tech R&D Credit
January 5, 2026
- Meiji Restarts Domestic 6-APA Production after 31-Year Hiatus
January 5, 2026
- Chuikyo OKs Medical Materials Reform Outline, Price Hikes Possible for Loss-Making Devices
January 5, 2026
- Industry Leaders Call for Proper Rewards for Innovation in New Year Messages
January 5, 2026
- MHLW FY2026 Budget Hits Record 35 Trillion Yen, Drug Discovery Support Set at 7.1 Billion Yen
January 5, 2026
- Meiji Files NDA for Nacubactam in Japan
January 5, 2026
- Generic Use Rate Rises Further to 89.5% in July-September: JGA
January 5, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…